AI Engines For more Details: Perplexity Kagi Labs You
Prevention and Treatment of Coccidiosis: Amprolium is effective against several species of Eimeria parasites that cause coccidiosis in poultry, cattle, sheep, goats, and other livestock. It works by blocking the replication and development of the parasites within the host animal's intestinal cells, thereby preventing the spread of the infection and reducing its severity.
Anticoccidial Activity: Amprolium is classified as an anticoccidial drug, meaning it specifically targets coccidia parasites without affecting other types of pathogens. It is commonly used in both prophylactic (preventive) and therapeutic (treatment) regimens to control coccidiosis outbreaks in commercial poultry and livestock operations.
Mode of Action: Amprolium acts by interfering with the parasite's ability to utilize thiamine (vitamin B1), which is essential for its metabolism and reproduction. By inhibiting thiamine uptake, amprolium disrupts the energy production and cellular processes of the coccidia, leading to their death and eventual clearance from the host's intestinal tract.
Oral Administration: Amprolium is typically administered orally, either as a liquid solution or as medicated feed or water, depending on the species and age of the animals being treated. It is absorbed poorly from the gastrointestinal tract, resulting in high concentrations within the intestinal lumen where the coccidia reside.
Safety and Tolerance: Amprolium is generally well-tolerated by poultry and livestock when used at recommended doses. However, overdose or prolonged administration may lead to adverse effects such as reduced feed intake, growth retardation, or thiamine deficiency in susceptible animals. It is important to follow label instructions and dosage recommendations carefully to avoid toxicity.
Withdrawal Period: In some countries, withdrawal periods may be required for animals treated with amprolium before their products (e.g., meat, milk, eggs) can be consumed by humans. This ensures that any residues of the medication are sufficiently eliminated from the animal's tissues or products to meet regulatory standards for food safety.
Combination Products: Amprolium is often formulated in combination with other anticoccidial agents or additives, such as flavomycin or bambermycins, to enhance its efficacy or provide additional benefits such as growth promotion or prevention of secondary bacterial infections.
Resistance Management: Prolonged or indiscriminate use of amprolium and other anticoccidial drugs can lead to the development of drug-resistant strains of coccidia, reducing the effectiveness of treatment options. Therefore, prudent use practices and rotation of different classes of anticoccidials are recommended to minimize the risk of resistance emergence.
Consultation with Veterinarian: The use of amprolium and other veterinary medications should always be guided by a veterinarian familiar with the specific needs and conditions of the animals being treated. They can provide tailored treatment protocols, monitor treatment efficacy, and address any concerns regarding medication safety or potential interactions with other drugs.
Rank | Probiotic | Impact |
---|---|---|
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Ruminococcus | genus | Decreases |
0 | 1 | Escherichia | genus | Decreases |
0 | 1 | Shigella | genus | Decreases |
0 | 1 | Coprococcus | genus | Decreases |
0 | 1 | Bacteroides | genus | Decreases |
0 | 1 | Lacticaseibacillus | genus | Decreases |
0 | 1 | Roseburia | genus | Decreases |
0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O103 | serogroup | Decreases |
0 | 1 | Escherichia coli O111 | serogroup | Decreases |
0 | 1 | Escherichia coli O119 | serogroup | Decreases |
0 | 1 | Escherichia coli O121 | serogroup | Decreases |
0 | 1 | Escherichia coli O145 | serogroup | Decreases |
0 | 1 | Escherichia coli O155 | serogroup | Decreases |
0 | 1 | Escherichia coli O157 | serogroup | Decreases |
0 | 1 | Escherichia coli O177 | serogroup | Decreases |
0 | 1 | Escherichia coli O26 | serogroup | Decreases |
0 | 1 | Escherichia coli O3 | serogroup | Decreases |
0 | 1 | Escherichia coli O43 | serogroup | Decreases |
0 | 1 | Escherichia coli O5 | serogroup | Decreases |
0 | 1 | Escherichia coli O78 | serogroup | Decreases |
0 | 1 | Escherichia coli O86 | serogroup | Decreases |
0 | 1 | Escherichia coli O91 | serogroup | Decreases |
0 | 1 | Escherichia coli H20 | serotype | Decreases |
0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
1 | 0 | Ruminococcus bromii | species | Decreases |
1 | 0 | Escherichia coli | species | Decreases |
1 | 0 | Bacteroides xylanisolvens | species | Decreases |
1 | 0 | Coprococcus comes | species | Decreases |
1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
0 | 1 | Shigella dysenteriae | species | Decreases |
0 | 1 | Shigella flexneri | species | Decreases |
0 | 1 | Escherichia albertii | species | Decreases |
0 | 1 | Escherichia fergusonii | species | Decreases |
0 | 1 | Bacteroides luhongzhouii | species | Decreases |
0 | 1 | Shigella boydii | species | Decreases |
1 | 0 | Bacteroides fragilis | species | Decreases |
0 | 1 | Bacteroides sp. DH3716P | species | Decreases |
0 | 1 | Bacteroides faecium | species | Decreases |
0 | 1 | Shigella sonnei | species | Decreases |
0 | 1 | Bacteroides caecimuris | species | Decreases |
0 | 1 | Escherichia marmotae | species | Decreases |
0 | 1 | Escherichia sp. E4742 | species | Decreases |
0 | 1 | Bacteroides ovatus | species | Decreases |
0 | 1 | Coprococcus catus | species | Decreases |
0 | 1 | Dorea longicatena | species | Decreases |
1 | 0 | Roseburia intestinalis | species | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
ADHD | 0.5 | 0.2 | 1.5 |
Age-Related Macular Degeneration and Glaucoma | 0 | 0 | |
Allergic Rhinitis (Hay Fever) | 0.4 | 0.6 | -0.5 |
Allergies | 1.7 | 1.1 | 0.55 |
Allergy to milk products | 1.3 | 0.5 | 1.6 |
Alzheimer's disease | 1.4 | 1.4 | 0 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.8 | 1 | -0.25 |
Ankylosing spondylitis | 1.2 | 0.5 | 1.4 |
Anorexia Nervosa | 0.4 | 0.7 | -0.75 |
Antiphospholipid syndrome (APS) | 0.6 | 0.6 | |
Asthma | 0.9 | 0.2 | 3.5 |
Atherosclerosis | 1.3 | 0.1 | 12 |
Atrial fibrillation | 0.9 | 0.6 | 0.5 |
Autism | 1.4 | 1.9 | -0.36 |
Autoimmune Disease | 0.5 | 0 | 0 |
benign prostatic hyperplasia | 0.5 | 0.1 | 4 |
Biofilm | 0.6 | 0.6 | |
Bipolar Disorder | 1 | 0.6 | 0.67 |
Brain Trauma | 0.6 | -0.6 | |
Breast Cancer | 0.6 | 0.6 | |
Cancer (General) | 0.3 | -0.3 | |
Carcinoma | 0.8 | 0.5 | 0.6 |
Celiac Disease | 0.9 | 0.5 | 0.8 |
Cerebral Palsy | 0.1 | 0.6 | -5 |
Chronic Fatigue Syndrome | 2 | 1.2 | 0.67 |
Chronic Kidney Disease | 0.7 | 0.2 | 2.5 |
Chronic Lyme | 0.2 | -0.2 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.7 | 0.2 | 2.5 |
Chronic Urticaria (Hives) | 0.8 | 0.2 | 3 |
Coagulation / Micro clot triggering bacteria | 1 | 0.4 | 1.5 |
Cognitive Function | 0.5 | 0 | 0 |
Colorectal Cancer | 2 | 0.7 | 1.86 |
Constipation | 1 | 0 | 0 |
Coronary artery disease | 1.4 | 0.5 | 1.8 |
COVID-19 | 1.7 | 1.7 | 0 |
Crohn's Disease | 2.2 | 0.9 | 1.44 |
Cushing's Syndrome (hypercortisolism) | 0.1 | -0.1 | |
cystic fibrosis | 0.8 | 0.2 | 3 |
d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
deep vein thrombosis | 1.3 | 0.6 | 1.17 |
Depression | 2.2 | 1.9 | 0.16 |
Eczema | 0.5 | 0.2 | 1.5 |
Endometriosis | 1.3 | 1.1 | 0.18 |
Epilepsy | 1.3 | 0.1 | 12 |
erectile dysfunction | 0.6 | 0.6 | |
Fibromyalgia | 0 | 0.5 | 0 |
Functional constipation / chronic idiopathic constipation | 2 | 0.9 | 1.22 |
gallstone disease (gsd) | 1.4 | 0 | 0 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 0.2 | |
Generalized anxiety disorder | 1.3 | 0.3 | 3.33 |
Gout | 1 | 0.3 | 2.33 |
Graves' disease | 0.5 | 0.6 | -0.2 |
Gulf War Syndrome | 0.2 | 0.2 | 0 |
Halitosis | 0.1 | 0.1 | |
Hashimoto's thyroiditis | 0.7 | 0.1 | 6 |
Heart Failure | 1.7 | 0.5 | 2.4 |
Hidradenitis Suppurativa | 0.1 | 0.1 | |
High Histamine/low DAO | 0.6 | 0.4 | 0.5 |
hypercholesterolemia (High Cholesterol) | 0.6 | 0.6 | |
hyperglycemia | 1 | 0.1 | 9 |
hypertension (High Blood Pressure | 1 | 0.9 | 0.11 |
Hypothyroidism | 0.2 | -0.2 | |
Hypoxia | 0.1 | 0.1 | |
IgA nephropathy (IgAN) | 0.5 | 0.1 | 4 |
Inflammatory Bowel Disease | 1.9 | 2.1 | -0.11 |
Insomnia | 0.3 | 0.7 | -1.33 |
Intelligence | 0.9 | 0.9 | |
Intracranial aneurysms | 0.5 | 0.2 | 1.5 |
Irritable Bowel Syndrome | 1.8 | 0.8 | 1.25 |
ischemic stroke | 1.1 | 0.6 | 0.83 |
Liver Cirrhosis | 1.7 | 1.3 | 0.31 |
Long COVID | 0.7 | 1.3 | -0.86 |
Low bone mineral density | 0.2 | -0.2 | |
Lung Cancer | 0.5 | 0.4 | 0.25 |
Lymphoma | 0.5 | 0.5 | |
Mast Cell Issues / mastitis | 0.5 | 0.6 | -0.2 |
ME/CFS with IBS | 0.7 | -0.7 | |
ME/CFS without IBS | 0.1 | 0.2 | -1 |
Menopause | 0.1 | 0 | 0 |
Metabolic Syndrome | 1.9 | 0.9 | 1.11 |
Mood Disorders | 1.6 | 1.8 | -0.13 |
Multiple Sclerosis | 0.9 | 0.9 | 0 |
Multiple system atrophy (MSA) | 0.4 | -0.4 | |
myasthenia gravis | 0.5 | 0 | 0 |
neuropathic pain | 0.2 | -0.2 | |
Neuropathy (all types) | 0.3 | -0.3 | |
neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.7 | 0.7 | 1.43 |
NonCeliac Gluten Sensitivity | 0.1 | 0.1 | 0 |
Obesity | 1.7 | 1.2 | 0.42 |
obsessive-compulsive disorder | 2 | 0.3 | 5.67 |
Osteoarthritis | 0.4 | 0.5 | -0.25 |
Osteoporosis | 1 | 0.1 | 9 |
Parkinson's Disease | 2.2 | 1.2 | 0.83 |
Polycystic ovary syndrome | 2 | 1.2 | 0.67 |
Postural orthostatic tachycardia syndrome | 0.2 | -0.2 | |
Primary sclerosing cholangitis | 0.1 | 0.7 | -6 |
Psoriasis | 1.1 | 0.3 | 2.67 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.8 | 0.5 | 2.6 |
Rosacea | 0.4 | 0 | 0 |
Schizophrenia | 0.7 | 0.7 | 0 |
scoliosis | 0.7 | 0.4 | 0.75 |
Sjögren syndrome | 0.5 | 0.1 | 4 |
Sleep Apnea | 0.7 | 0.3 | 1.33 |
Slow gastric motility / Gastroparesis | 1.1 | 1.1 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 0.9 | |
Stress / posttraumatic stress disorder | 0.9 | 0.3 | 2 |
Systemic Lupus Erythematosus | 0.9 | 0.4 | 1.25 |
Tic Disorder | 0.4 | 0.4 | |
Tourette syndrome | 0.1 | -0.1 | |
Type 1 Diabetes | 1.4 | 0.6 | 1.33 |
Type 2 Diabetes | 1.9 | 1.6 | 0.19 |
Ulcerative colitis | 1.5 | 1 | 0.5 |
Unhealthy Ageing | 0.5 | 0.2 | 1.5 |
Vitiligo | 0.7 | 0.3 | 1.33 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]